NIDA Notes Advanced Search

In a clinical trial, N-acetylcysteine did not help adults reduce their cannabis use, despite having been effective for adolescents in a previous trial. The results indicated that if adults are able to benefit from the medication, they will likely require a different treatment regimen than adolescents.

Dr. Kevin M. Gray discusses why it’s the perfect time for discovering new evidence-based treatments for marijuana dependence. In an accompanying podcast, he discusses a clinical trial that examines NAC’s potential as a treatment for marijuana dependence among adults.

A trial of buprenorphine/naloxone (Bup/Nx) showed no evidence that the medicine was associated with liver damage. The drug gave results similar to those of methadone. The study data indicate that although most patients can be treated safely with either methadone or Bup/Nx without major concern for liver injury, clinicians are advised to continue to monitor the liver health of their patients who are on methadone or Bup/Nx therapy.

Patients were more likely to take a rapid HIV test when substance abuse treatment programs offered the test onsite rather than referred for offsite testing. Patients were equally likely to accept and learn their HIV status whether the offer of onsite testing was accompanied by 30 minutes of risk reduction counseling or by 5 minutes of brief information on the testing procedure. Onsite testing accompanied by brief information was cost effective, taking into account the projected lifetime costs of treatment and the gains in health and longevity for detected cases.

Pregnant women who received financial incentives to refrain from smoking during late pregnancy were more successful at remaining abstinent and less likely to have babies with low birth weight, according to data from three trials.

Women with post-traumatic stress disorder (PTSD) who abused drugs responded better to substance abuse treatment after their PTSD symptoms improved, according to a recent study, which also found that reductions in substance abuse did not ease PTSD severity

NIDA’s Women and Sex/Gender Differences Research Program focuses on gender-specific addiction risk factors and treatment needs.

Dr. Thomas Kosten of Baylor College of Medicine and Dr. Peter Burkhard of the University of Connecticut are the recipients of NIDA’s 2011 Avant-Garde Awards for Innovative Medication Development Research. Dr. Kosten is developing a vaccine against methamphetamine abuse and Dr. Burkhard is developing a vaccine to counter nicotine addiction.

Discusses research that compares multiple sessions of motivational and behavioral training with that of a single intervention among male and female substance abusers to reduce high-risk sexual behaviors.

Recognizes the 2010 Distinguished University Professor awardee, Dr. Kathleen T. Brady, who studies co-occurring substance abuse and mental health disorders and their treatment.

Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.

Reports on a study investigating the benefits of extended opioid maintenance therapy that included drug counseling and 12 weeks of therapy with buprenorphine and naloxone.

Summarizes a study on the use of incentives to encourage abstinence among methadone maintenance patients in outpatient programs.

Presents an overview of the research underway to investigate medication and behavioral therapies for co-occurring disorders.

Reports on a study investigating the use of incentives in the form of prizes to motivate outpatients to stay in behavioral therapy and remain drug free.